Top buy and sell ideas by Ashwani Gujral, Sudarshan Sukhani for short term
Ashwani Gujral of ashwanigujral.com recommends buying Cadila Healthcare with a stop loss of Rs 430, target at Rs 456 and Biocon with a stop loss of Rs 460, target at Rs 485.
Cadila: Rebound in domestic formulations to add to US sales, drive earnings
In the US, Cadila is expected to gain from improvement in realisation for its product range led by drug shortages CADILA HEALTHCARE LTD. - 532321 - Shareholding for the Period Ended September 30, 2020
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here CADILA HEALTHCARE LTD. - 532321 - Compliance Certificate For The Half Year Ended On September 30, 2020
Compliance Certificate for the half year ended on September 30, 2020 CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus launches India's first pressurized Metered Dose Inhaler for patients suffering from Chronic Obstructive Pulmonary Disease CADILA HEALTHCARE LTD. - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (DIP) Regulations, 2018
Top buy and sell ideas by Ashwani Gujral, Sudarshan Sukhani, Mitessh Thakkar for short term
Mitessh Thakkar of mitesshthakkar.com suggests buying Cadila Healthcare with a stop loss of Rs 408, target at Rs 428 and Dabur India with a stop loss of Rs 509, target at Rs 545. Coronavirus vaccine update: Which countries are leading the race?
Coronavirus vaccine update: In India, there are three COVID-19 vaccines under human trials--Bharat Biotech's COVAXIN, Oxford's COVDSHIELD, and Zydus Cadila's ZyCoV-D. Serum Institute has already begun a phase-3 trial of Oxford vaccine candidates at 17 sites
COVID-19: Vaccine companies seek buying commitments from govt, global agencies to de-risk investment
Drug makers say it would help them plan better to create capacities. Three potential vaccines candidates from India -- Covishield of Serum Institute with license from AstraZeneca, Covaxin of Bharat Biotech, and ZyCov-D of Zydus Cadila -- have progressed into human trials phase. CADILA HEALTHCARE LTD. - 532321 - Closure of Trading Window
The trading window shall remain closed from October 1, 2020 till 48 hours after the declaration of unaudited financial results for the quarter / half year ending on September 30, 2020 for the Directors and Designated Persons and their immediate relatives, for trading in the equity shares of the Company.